A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results

Andrew Zolopa, Paul E. Sax, Edwin Dejesus, Anthony Mills, Calvin Cohen, David Wohl, Joel E. Gallant, Hui C. Liu, Andrew Plummer, Kirsten L. White, Andrew K. Cheng, Martin S. Rhee, Javier Szwarcberg

Research output: Contribution to journalArticlepeer-review

Abstract

We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF, n = 352). At week 48, EVG/COBI/FTC/TDF was noninferior to EFV/FTC/TDF (88% vs 84%, difference +3.6%, 95% confidence interval: -1.6% to 8.8%). Virologic success (HIV-1 RNA

Original languageEnglish (US)
Pages (from-to)96-100
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume63
Issue number1
DOIs
StatePublished - May 1 2013

Keywords

  • cobicistat
  • efficacy
  • HIV
  • phase 3 randomized trial
  • safety
  • stribild

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results'. Together they form a unique fingerprint.

Cite this